# A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

> **NCT06004245** · PHASE1 · RECRUITING · sponsor: **Vividion Therapeutics, Inc.** · enrollment: 280 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Colorectal Cancer

## Interventions

- **DRUG:** VVD-133214
- **DRUG:** Pembrolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06004245
- **Lead sponsor:** Vividion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-25
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004245, "A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06004245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*